Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

$1.08

DILUTED ADJUSTED INCOME PER COMMON

SHARE $1.18 $0.92

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING 68,118 66,931

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING-ASSUMING DILUTION 78,920 79,030

Notes to Reconciliation of GAAP Net Income to Adjusted Net Income

(1) To exclude the on-going amortization of acquired intangible assets ($24.0 million in 2008; $22.3 million in 2007), accelerated depreciation related to the CIMA LABS restructuring ($1.6 million in 2008), accelerated depreciation related to the proposed divestiture at the Mitry-Mory facility ($2.9 million in 2008), and the write-off of purchase commitments in excess of estimated requirements ($26.0 million in 2008).

(2) In 2008, to exclude accelerated depreciation related to the proposed divestiture at the Mitry-Mory facility. In 2007, to exclude the recognition of a milestone related to the FDA's acceptance of our NDA filing for TREANDA (bendamustine HCl).

(3) To exclude charges related to the estimated termination payments due to Takeda Pharmaceuticals North America, Inc.

(4) In 2008, to exclude charges related to the settlement of investigations by the Offices of the Attorney General of Connecticut and Massachusetts and estimated relator attorney fees. In 2007, to exclude the reserve established for the minimum liability related to the potential settlement of the investigations by the U.S. Attorney's Office.

(5) To exclude the forgiveness of a mortgage loan by the Pennsylvania Industrial Development Board ("PIDA").

(6) To exclude the accrued interest related to the settlement reached with the U.S. Attorney's Office.

(7) To exclude costs related to the CIMA LABS restructuring announced in January 2008.

(8) To reflect the tax effect of pre-tax adjustments at the applicable tax rates and certain other
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 5, 2015  In response to the incorrect assertions ... FL on February 12, 2015. Impeto Medical ... financial health and their SUDOSCAN® devices have been proven ... Impeto prefers to have the courts decide this dispute ... than 40 articles written by Key Opinion Leaders, published ...
(Date:3/4/2015)... In an article published and posted online ... Security review the clinical aspects of diseases caused by ... The article, "Clinical Management of Potential Bioterrorism-Related Conditions," was ... the New England Journal of Medicine . ... and Tom Inglesby—review the clinical management of conditions resulting ...
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biologics and Biosimilars Industry Report ... The Global Biologics and Biosimilars Industry ... on the current state of the biologics and ... basic overview of the industry including definitions, classifications, ...
(Date:3/4/2015)... March 4, 2015  BioClinica®, Inc., a ... provider, today announced that clinical trial professionals ... at its annual European User Conference in ... discuss the use of its eClinical technologies ... technologies include: the Microsoft Office-Smart OnPoint CTMS; ...
Breaking Biology Technology:Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2Latest Clinical Information On Bioterrorism Threats 2Global Biologics and Biosimilars Industry Report 2015-2020 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3
... 11 Altogen Biosystems,( http://www.altogen.com ) announced ... Las Vegas, NV, Altogen Custom Services focus ... Interference (RNAi) services, generation of stably-expressing cell,lines, ... the company will draw upon their unique ...
... affordable and accessible to all researchers, HUNTSVILLE, ... that Harvard Medical School and the University of ... Each University,purchased access to whole genome human and ... and distributed by Open Biosystems., (Logo: ...
... China-based R&D and production platform and Datascope,s strong US-based ... direct sales and service network, Provides powerful ... ... SHENZHEN, China, March 11 /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited (NYSE: ...
Cached Biology Technology:Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services 2Open Biosystems' Open Access RNAi Program Adopted by Harvard Medical School and University of North Carolina 2Mindray to Acquire Datascope's Patient Monitoring Business for US$202 million 2Mindray to Acquire Datascope's Patient Monitoring Business for US$202 million 3Mindray to Acquire Datascope's Patient Monitoring Business for US$202 million 4Mindray to Acquire Datascope's Patient Monitoring Business for US$202 million 5Mindray to Acquire Datascope's Patient Monitoring Business for US$202 million 6
(Date:2/23/2015)... Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... patent 62114357 for DISTRIBUTED VOICE DIRECTED PAYMENT ... introduces a new groundbreaking payment method. Payment accounts may ... may only be accessed if both the speech (the ...
(Date:2/12/2015)... MINNETONKA, Minn. , Feb. 12, 2015 /PRNewswire/ ... technology company specializing in clinical study management systems, ... Partner Program , further distinguishing iMedNet ... for Clinical Research Organizations (CROs) and healthcare consultants.  ... sales support, prospective customer referrals and numerous co-marketing ...
(Date:2/9/2015)...  Lintec of America recently announced an exclusive license ... macrostructures, including sheets, yarns and ribbons, developed at the ... the vast industrial resources of the global Lintec Group, ... of America is forming the Nano-Science and Technology Center ... on scaling up the manufacturing and commercialization of nano ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... good news from University of Illinois broccoli researchers this ... broccoli lacks the ability to form sulforaphane, the cancer-fighting ... how the food industry can act to restore the ... that companies can use to make frozen broccoli as ...
... losing about 1.6 million tonnes of carbon per year from ... and carbon accounts, according to new research.,Top soil is rich ... by events such as the ,Red Dawn, in Sydney in ... atmosphere it changes the amount and location of soil carbon. ...
... with carpal tunnel syndrome one of the most common ... research collaboration led by an Arizona State University biomedical engineering ... and Mark Ross were recently awarded a grant of $93,000 ... to quantify the effects of carpal tunnel release surgery on ...
Cached Biology News:Illinois scientists put cancer-fighting power back into frozen broccoli 2Soil carbon 'blowing in the wind' 2ASU-Mayo research project targets carpal tunnel syndrome diagnosis 2
... the data from any one of IITC NIBP ... The final data is sent from the amplifier ... automatic for Systolic, Mean, Heart Rate while the ... always in the position to override the automatic ...
Sirtuin 7 (SIRT7) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: Other Recommended Storage: Long term: -20C; Short term: +4C...
... DNA microarrays designed for your specific applications ... Paraflo microfluidic synthesis platform. Thousands of customer ... LC Sciences can provide assistance with custom ... part of our comprehensive Custom DNA Microarray ...
... microplate sealer with an integrated in-line plate ... a variety of configurations and sealing capabilities. ... stacker and 240-plate storage capacity , Integrated ... small workcells , Handles all SBS microplates ...
Biology Products: